Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Journey Medical Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CLINICAL TRIAL ACHIEVED ALL THREE PRIMARY OBJECTIVES WITH NO SIGNIFICANT SAFETY ISSUES BEING REPORTED RESULTS INDICATE THAT EMROSI CAN BE SAFELY USED FOR UP TO 16 WEEKS WITH NO DETECTABLE IMPACT ON SKIN, GI TRACT OR VAGINAL MICROBIOTA FDA-APPROVED EMROSI (40 MG MINOCYCLINE HYDROCHLORIDE MODIFIED-RELEASE CAPSULES, 10 MG IMMEDIATE RELEASE AND 30 MG EXTENDED RELEASE) IS AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS SCOTTSDALE, ARIZ., DEC. 10, 2025 (GLOBE NEWSWIRE) -- JOURNEY MEDICAL CORPORATION (NASDAQ: DERM) (JOURNEY MEDICAL), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY PRIMARILY FOCUSED ON SELLING AND MARKETING U.S. FOOD AND DRUG ADMINISTRATION (FDA)-APPROVED PRESCRIPTION PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS, TODAY ANNOUNCED THAT RESULTS FROM THE PHASE 1 CLINICAL TRIAL (DFD-29-CD-006) ASSESSING THE IMPACT OF LOW-DOSE ORAL MINOCYCLINE (DFD-29 OR COMMERCIALLY KNOWN AS EMROSI) ON SKIN, GASTROINTESTINAL (GI) AND VAGINAL MICROFLORA IN HEALTHY ADULTS WERE PUBLISHED IN THE JOURNAL OF DRUGS IN DERMATOLOGY, A LEADING PEER-REVIEWED PUBLICATION IN CLINICAL DERMATOLOGY.

JOURNEY MEDICAL CORPORATION ANNOUNCES PUBLICATION OF CLINICAL TRIAL RESULTS ASSESSING THE IMPACT OF EMROSI (DFD-29) ON MICROBIAL FLORA OF HEALTHY ADULTS IN THE JOURNAL OF DRUGS IN DERMATOLOGY

THIRD QUARTER 2025 NET REVENUES WERE $17.6 MILLION EMROSI TOTAL PRESCRIPTIONS INCREASED 146% OVER THE SECOND QUARTER OF 2025 EMROSI NET REVENUES WERE $4.9 MILLION COMPANY TO HOLD CONFERENCE CALL TODAY AT 4:30 P.M. ET TO DISCUSS THE FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE SCOTTSDALE, ARIZ.

JOURNEY MEDICAL CORPORATION REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

COMPANY TO HOST CONFERENCE CALL TO DISCUSS FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 12, 2025 AT 4:30 P.M. ET COMPANY TO HOST CONFERENCE CALL TO DISCUSS FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 12, 2025 AT 4:30 P.M. ET

JOURNEY MEDICAL CORPORATION TO ANNOUNCE THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 12, 2025

FDA-APPROVED EMROSI (40 MG MINOCYCLINE HYDROCHLORIDE MODIFIED-RELEASE CAPSULES, 10 MG IMMEDIATE RELEASE AND 30 MG EXTENDED RELEASE) IS AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS

JOURNEY MEDICAL CORPORATION REPORTS COMBINED EMROSI (DFD-29) PHASE 3 CLINICAL TRIAL EFFICACY DATA ANALYSIS PRESENTED AT THE 2025 FALL CLINICAL DERMATOLOGY CONFERENCE

SCOTTSDALE, ARIZ., OCT. 08, 2025 (GLOBE NEWSWIRE) -- JOURNEY MEDICAL CORPORATION (JOURNEY MEDICAL OR THE COMPANY) (NASDAQ: DERM), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY PRIMARILY FOCUSED ON SELLING AND MARKETING U.S. FOOD AND DRUG ADMINISTRATION (FDA)-APPROVED PRESCRIPTION PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS, TODAY ANNOUNCED THAT MEMBERS OF JOURNEY MEDICAL'S MANAGEMENT TEAM WILL PARTICIPATE IN TWO OCTOBER 2025 INVESTOR CONFERENCES.

JOURNEY MEDICAL CORPORATION TO PARTICIPATE IN OCTOBER 2025 INVESTOR CONFERENCES

SCOTTSDALE, ARIZ., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- JOURNEY MEDICAL CORPORATION (JOURNEY MEDICAL OR THE COMPANY) (NASDAQ: DERM), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY PRIMARILY FOCUSED ON SELLING AND MARKETING U.S. FOOD AND DRUG ADMINISTRATION (FDA)-APPROVED PRESCRIPTION PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS, TODAY ANNOUNCED THAT CLAUDE MARAOUI, CO-FOUNDER, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN TWO SEPTEMBER 2025 INVESTOR CONFERENCES.

JOURNEY MEDICAL CORPORATION TO PARTICIPATE IN SEPTEMBER 2025 INVESTOR CONFERENCES

SCOTTSDALE, ARIZ., AUG. 18, 2025 (GLOBE NEWSWIRE) -- JOURNEY MEDICAL CORPORATION (NASDAQ: DERM) (JOURNEY MEDICAL, THE COMPANY, WE OR OUR), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY PRIMARILY FOCUSED ON SELLING AND MARKETING FDA-APPROVED PRESCRIPTION PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS, TODAY ANNOUNCED THAT CLAUDE MARAOUI, CO-FOUNDER, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT A CORPORATE OVERVIEW AT THE EMERGING GROWTH CONFERENCE ON WEDNESDAY, AUGUST 20, 2025 AT 12:35 P.M. ET. ALL SESSIONS WILL BE CONDUCTED VIRTUALLY THROUGH VIDEO WEBCASTS.

JOURNEY MEDICAL CORPORATION TO PRESENT AT THE EMERGING GROWTH CONFERENCE

S ECOND QUARTER 2025 REVENUES WERE $15.0 MILLION EMROSI NET SALES OF $2.8 MILLION GENERATED IN FIRST FULL QUARTER ON THE MARKET THE COMPANY JOINED THE RUSSELL 2000 AND RUSSELL 3000 INDEXES IN JUNE 2025 COMPANY TO HOLD CONFERENCE CALL TODAY AT 4:30 P.M. ET TO DISCUSS THE FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE SCOTTSDALE, ARIZ.

JOURNEY MEDICAL CORPORATION REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

SCOTTSDALE, ARIZ., AUG. 07, 2025 (GLOBE NEWSWIRE) -- JOURNEY MEDICAL CORPORATION (NASDAQ: DERM) (JOURNEY MEDICAL OR THE COMPANY, WE, OR OUR), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY THAT PRIMARILY FOCUSES ON SELLING AND MARKETING U.S. FOOD AND DRUG ADMINISTRATION (FDA)-APPROVED PRESCRIPTION PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS, TODAY ANNOUNCED THAT THE MANAGEMENT TEAM OF JOURNEY MEDICAL WILL RING THE CLOSING BELL AT THE NASDAQ MARKETSITE IN TIMES SQUARE ON MONDAY, AUGUST 11, 2025 AT 4:00 P.M. ET. JOURNEY MEDICAL IS CELEBRATING ITS 4-YEAR ANNIVERSARY AS A PUBLICLY TRADED COMPANY ON THE NASDAQ STOCK MARKET AND THE COMMERCIAL LAUNCH OF EMROSI (40 MG MINOCYCLINE HYDROCHLORIDE MODIFIED-RELEASE CAPSULES) FOR THE TREATMENT OF ROSACEA.

JOURNEY MEDICAL CORPORATION TO RING NASDAQ STOCK MARKET CLOSING BELL ON AUGUST 11

COMPANY TO HOST CONFERENCE CALL TO DISCUSS FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 12, 2025 AT 4:30 P.M. ET COMPANY TO HOST CONFERENCE CALL TO DISCUSS FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 12, 2025 AT 4:30 P.M. ET

Journey Medical Corporation

DERM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Journey Medical Corporation

DERM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DERM